Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 226-641-8 | CAS number: 5444-75-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
In the key study, the skin sensitisation properties of 2-ethylhexyl benzoate were tested in a GPMT according to OECD guideline 406 in compliance with GLP (Coleman, 2000).
In a preliminary range finding test, the suitable concentrations were evaluated for the intradermal injection and the patch testing. In the main study, Dunkin-Hartley guinea pigs were induced with a single intradermal injection of the test substance at 7.5% in Alembicol D and an epicutaneous occlusive application of the undiluted test substance at the flank 7 days later. Epicutaneous challenge exposure was conducted 20 days after the first induction for 24 h under occlusive conditions at 37.5 and 75% of the test substance applied on the flanks.
All test and control animals except one showed no skin reactions after 24 and 48 h. 1/10 test group animals showed a slight erythema at the 75% application site after 24 h. The positive control group was treated with 10% hexyl cinnamic aldehyde in Alembicol D and showed the expected results, thus confirming the sensitivity and reliability of the experiment.
Under the experimental conditions described, it was concluded, that no evidence of skin sensitisation properties were seen after treatment with the 2-ethylhexyl benzoate.
Furthermore, in a short abstract, the skin sensitisation properties of 2-ethylhexyl benzoate are described in an assay equivalent to OECD guideline 429 (Johnson, 2001).
In the local lymph node assay, the radiolabelled thymidine incorporation method was used. Concentrations of 3, 10 and 30% (w/v) of the test material in acetone in olive oil were tested in mice.
The resulting test/control ratios from the treatment groups were below the value which is recognized for a positive response (1.07, 1.00 and 2.41).
In summary, under the conditions described, no evidence of skin sensitisation properties was seen after treatment with 2-ethylhexyl benzoate.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- other: Only short abstract available. Lack of details on test material and method.
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- yes
- Remarks:
- lack of details on test material and method
- GLP compliance:
- yes
- Remarks:
- study protocol, experimental phases and report were not subject of Quality Assurance audit
- Type of study:
- mouse local lymph node assay (LLNA)
- Species:
- mouse
- Strain:
- not specified
- Sex:
- not specified
- Vehicle:
- other: acetone in olive oil
- Concentration:
- 3, 10 and 30% (w/v)
- No. of animals per dose:
- no data
- Details on study design:
- MAIN STUDY
ANIMAL ASSIGNMENT AND TREATMENT
- Name of test method: radiolabelled thymidine incorporation - Key result
- Parameter:
- other: Test / Control Ratio (CPM)
- Value:
- < 2.5
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- According to the authors, the test material is considered unlikely to be a skin sensitiser under the conditions of the test.
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 24 Jan - 25 Feb 2000
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP-Guideline study.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 406 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.6 (Skin Sensitisation)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPPTS 870.2600 (Skin Sensitisation)
- Deviations:
- no
- GLP compliance:
- yes
- Type of study:
- guinea pig maximisation test
- Justification for non-LLNA method:
- Vertberate study predates requirement to test in-vitro before vertebrate studies
- Species:
- guinea pig
- Strain:
- Dunkin-Hartley
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: D. Hall (Newchurch, Staffs, UK)
- Age at study initiation: 4-7 weeks
- Weight at study initiation: 362-435 g
- Housing: the animals were housed in groups of five in suspended metal cages with wire mesh floors.
- Diet: vitamin C enriched guinea-pig diet (Harlan Teklad 9600 FD2 SQC), ad libitum. In addition, hay was given thrice weekly.
- Water: drinking water, ad libitum
- Acclimation period: 5 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19-20
- Humidity (%): 38-58
- Photoperiod (hrs dark / hrs light): 12/12 - Route:
- intradermal and epicutaneous
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Preliminary study:
Intradermal: 0.1-10%; epicutaneous: 25-100%
Main study:
Induction:
Intradermal: 7.5%; epicutaneous: 100%
Challenge:
37.5 and 75% - Route:
- epicutaneous, occlusive
- Vehicle:
- other: Alembicol D
- Concentration / amount:
- Preliminary study:
Intradermal: 0.1-10%; epicutaneous: 25-100%
Main study:
Induction:
Intradermal: 7.5%; epicutaneous: 100%
Challenge:
37.5 and 75% - No. of animals per dose:
- Preliminary study
6
Main study
5 (controls), 10 (in test group) - Details on study design:
- MAIN STUDY
A. INDUCTION EXPOSURE
- No. of exposures: 2 (intradermal and epicutaneous, respectively)
- Exposure period: single injection (intradermal) and 48 h (epicutaneous)
- Test groups:
Intradermal (3 pairs of injections):
Injection 1: a 1:1 mixture (v/v) FCA/water
Injection 2: test substance in Alembicol D
Injection 3: test substance in a 1:1 mixture (v/v) FCA/water
Epicutaneous: test substance
- Control group:
Intradermal (3 pairs of injections):
Injection 1: a 1:1 mixture (v/v) FCA/water
Injection 2: Alembicol D
Injection 3: Alembicol D in a 1:1 mixture (v/v) FCA/water
Epicutaneous: Alembicol D
- Site: flank
- Frequency of applications: every 7 days
- Duration: Day 0-8
- Concentrations: intradermal 7.5%, epicutaneous 100%
B. CHALLENGE EXPOSURE
- No. of exposures: 1
- Day(s) of challenge: 20
- Exposure period: 24 h
- Test groups: test substance
- Control group: test substance
- Site: left flank
- Concentrations: 37.5 and 75% (v/v)
- Evaluation (hr after challenge): 48 and 72 h
OTHER:
The preliminary investigations indicated that the neat test substance applied topically did not produce skin irritation. Therefore, six days after the injections, the injection site was clipped and shaved free of hair and the site was pre-treated by gentle rubbing with 0.5 mL per site of 10% (w/w) sodium lauryl sulphate in petrolatum. - Challenge controls:
- The control group is actually a challenge control.
- Positive control substance(s):
- yes
- Remarks:
- hexyl cinnamic aldehyde (induction: 10% intradermal; epicutaneous 100%; challenge: 100%)
- Positive control results:
- The positive control substance (10% hexyl cinnamic aldehyde in Alembicol D (intradermal), 50 and 100% (challenge)) induced positive reactions in 9/10 animals (90%), thus confirming the sensitivity and reliability of the experimental technique.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 0% (induction); 37.5 and 75% (challenge)
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0% (induction); 37.5 and 75% (challenge). No with. + reactions: 0.0. Total no. in groups: 5.0.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 7.5 and 100% (induction: intradermal and epicutaneous); 37.5 and 75% (challenge)
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- slight erythema at application site (75% of the test material) in 1/10 animals
- Remarks on result:
- other: see Remark
- Remarks:
- Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 7.5 and 100% (induction: intradermal and epicutaneous); 37.5 and 75% (challenge). No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: slight erythema at application site (75% of the test material) in 1/10 animals.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 0% (induction); 37.5 and 75% (challenge)
- No. with + reactions:
- 0
- Total no. in group:
- 5
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0% (induction); 37.5 and 75% (challenge). No with. + reactions: 0.0. Total no. in groups: 5.0.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 7.5 and 100% (induction: intradermal and epicutaneous); 37.5 and 75% (challenge)
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 7.5 and 100% (induction: intradermal and epicutaneous); 37.5 and 75% (challenge). No with. + reactions: 0.0. Total no. in groups: 10.0.
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- CLP: not classified
Referenceopen allclose all
Table 1. Results of local lymph node assay.
Concentration of test material |
CPM/lymph node (x10-2) |
Test/control ratio |
Vehicle |
1.67 |
N/A |
3% (w/v) |
1.78 |
1.07 |
10% (w/v) |
1.67 |
1.00 |
30% (w/v) |
4.02 |
2.41 |
CPM - counts per minute
No signs of ill health or toxicity were observed.
After intradermal injections with FCA necrosis was recorded in test and control animals. Slight irritation was seen in test animals receiving intradermal 7.5% of the test substance in Alembicol D and in control animals.
After topical application, slight erythema was observed in 5/10 animals and well defined erythema in 4/10 animals; no erythema was seen in the control animals. After challenge, slight erythema was noted for one test animal at the 24 h reading only. The reaction was considered to be a background irritation.
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
Justification for selection of skin sensitisation endpoint:
The key study is GLP compliant and of high quality (Klimisch score = 1).
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
- Additional information:
This information is not available.
Justification for classification or non-classification
The available data on the skin sensitising potential of 2-ethylhexyl benzoate do not meet the criteria for classification according to Regulation (EC) 1272/2008 or Directive 67/548/EEC, and are therefore conclusive but not sufficient for classification.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.